Disease Modification of Asthma by molecules derived from TB bacteria

结核菌（mTB）存在于全球约20亿人中;它们已经进化了数千年，通过产生调节宿主免疫系统的蛋白质来隐藏在体内。Peptinnovate的方法是释放这些蛋白质的抗炎活性，并开发治疗哮喘和COPD等衰弱性疾病的新药。基于进化，自然的创造力和使用Peptinnovate的药物发现和开发技能，我们已经将这些蛋白质修饰成更多的药物样分子，并正在开发候选分子，PIN 201104，目的根据小鼠屋尘螨（HDM）的令人兴奋的临床前数据，哮喘模型的领先候选人PIN 201104 Peptinnovate将进展分子进入体内和体外作用机制研究;这些研究将导致体外生物标志物测定用于健康志愿者的临床研究，并指导严重哮喘患者中PIN 201104的表型定位，目的·在鼠哮喘模型中进行体内研究以确定PIN 201104是否影响气道高反应性（哮喘）·进行体内研究以确定PIN 201104用于治疗哮喘的适当给药方案和递送途径。结果和影响炎症性疾病治疗的全球市场是巨大的（> 700亿美元），然而最近的安全性恐慌归因于一些关键药物。Peptinnovate在潜在治疗选择方面的巨大转变将对数百万患者的生活产生深远影响，减轻医疗保健提供者的负担，并帮助建立一家可持续的英国生物技术公司

Tuberculosis bacteria (mTB) are present in about 2 billion people worldwide; they haveevolved over millennia to remain hidden in the body by producing proteins that modulate thehost's immune system. These proteins have been shown to interact with and reduce the body'snatural inflammatory processes.Peptinnovate’s innovationPeptinnovate’s approach is to unlock the anti-inflammatory activity of these proteins and todevelop new medicines for debilitating diseases such as asthma and COPD. Building onevolution, nature's ingenuity and employing Peptinnovate’s drug discovery and developmentskills we have modified these proteins to more drug-like molecules and are progressing thecandidate molecule, PIN201104, to the clinic.AimsFollowing exciting preclinical data in the murine house dust mite (HDM) asthma model forthe lead candidate PIN201104 Peptinnovate will progress the molecule into in vivo and invitro mechanism of action studies to; unravel the mechanism of action of the peptide inasthma animal models and translate this mechanism into an in vitro setting in human cells.These studies will then lead to an in vitro biomarker assay for use in clinical studies in healthyvolunteers and guide phenotypic positioning of PIN201104 in severe, steroid refractiveasthma.Objectives• To perform in vivo studies in murine asthma models to determine if PIN201104effects airway hyperreactivity (asthma)• To perform in vivo studies to ascertain the appropriate dosing regimen and route ofdelivery for PIN201104 for the treatment of asthmaBenefits, outcomes and impactsThe worldwide market for inflammatory disease treatment is substantial (>$70 billion),however recent safety scares have been attributed to a number of key drugs. Peptinnovate’sparadigm shift in potential treatment options will have a profound impact on the lives ofmillions of patients, reducing the burden on the healthcare providers and helping to build asustainable UK biotech company